Acro Biomedical (ACBM) Debt to Equity (2016 - 2022)

Acro Biomedical's Debt to Equity history runs 7 years deep, the most recent figure standing at $0.32 for Q4 2022.

• In Q4 2022, Debt to Equity rose 402.99% year-over-year to $0.32; the TTM figure through Dec 2022 stood at $0.32 (up 402.99% YoY), while the FY2022 annual figure was $0.32, up 402.99% from the prior year.
• Debt to Equity was $0.32 for Q4 2022 at Acro Biomedical, up from $0.16 in the prior quarter.
• In the past five years, Debt to Equity ranged from a high of $0.41 in Q1 2021 to a low of $0.0 in Q4 2018.
• Historically, Debt to Equity has averaged $0.13 across 5 years, with a median of $0.09 in 2019.
• The sharpest annual moves came in 2018 and 2019: Debt to Equity sank 96.0% in 2018, then jumped 1077.2% in 2019.
• A 5-year view of Debt to Equity shows it stood at $0.0 in 2018, then surged by 1077.2% to $0.03 in 2019, then surged by 975.98% to $0.35 in 2020, then tumbled by 81.81% to $0.06 in 2021, then surged by 402.99% to $0.32 in 2022.
• The last three Debt to Equity figures came in at $0.32 (Q4 2022), $0.16 (Q3 2022), and $0.04 (Q2 2022), per Business Quant data.